Search

Displaying results 5901 - 5910 of 7897 in total
  1. Drug

    Frespaciguat

    go.drugbank.com/drugs/DB21683
    Investigational

    Frespaciguat is a small molecule drug. The usage of the INN stem '-ciguat' in the name indicates that Frespaciguat is a guanylate cyclase activator and stimulator. … Frespaciguat has a monoisotopic molecular weight of 608.14 Da.

  2. Drug

    Crizanlizumab

    go.drugbank.com/drugs/DB15271
    ApprovedInvestigational

    [T734] Currently, patients are prescribed [hydroxyurea] to raise levels of fetal hemoglobin as a method of reducing morbidity and mortality. … [L10097] Sickle cell disease is a genetically inherited condition prevalent in the Middle East, Africa, and certain parts of India.

  3. Drug

    PPI-1019

    go.drugbank.com/drugs/DB05832
    Investigational

    Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.

  4. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause … In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265.

  5. Drug

    Nizubaglustat

    go.drugbank.com/drugs/DB21603
    Investigational

    Nizubaglustat is a small molecule drug. The usage of the INN stem '-glustat' in the name indicates that Nizubaglustat is a ceramide glucosyltransferase inhibitor. … Nizubaglustat has a monoisotopic molecular weight of 433.23 Da.

    Synonyms: AZ-3102
  6. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … II, randomized, controlled, adaptive, double-blind and multicenter study to evaluate the safety, reactogenicity and immunogenicity, of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a

  7. Drug

    Mesterolone

    go.drugbank.com/drugs/DB13587
    Investigational

    Experiments of mesterolone serving as a potential treatment of depression are still undergoing. … It is inactivated by 3α-hydroxysteroid dehydrogenase in skeleta muscules so it is considered a weak androgen. It is not a substrate for aromatase so it is not converted into estrogen.

  8. Drug

    Muraglitazar

    go.drugbank.com/drugs/DB06510
    Investigational

    In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment is associated with a substantial reduction in triglycerides (TGs), an increase in HDL-C, and a modest decrease … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes.

  9. Drug

    Cyclic GMP

    go.drugbank.com/drugs/DB02315
    Experimental

    It is a cellular regulatory agent and has been described as a second messenger. … Cyclic guanosine monophosphate (Cyclic GMP) is a guanine nucleotide containing one phosphate group which is esterified to the sugar moiety in both the 3'- and 5'-positions.

  10. Drug

    Sotagliflozin

    go.drugbank.com/drugs/DB12713
    ApprovedInvestigational

    1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m<sup>2</sup>. … [L39734] A similar approval has also been sought in the US, but the FDA has since published a proposal to refuse the approval because the data submitted did not show that it was safe under the proposed